FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W869271457> ?p ?o ?g. }

• W869271457 abstract "Background: Treatment goals of metastatic breast cancer (MBC) are to prolong survival and improve health-related quality of life (HRQOL). Current standard first-line chemotherapy for MBC are the taxanes or anthracyclines; however treatment-related adverse events greatly reduce HRQOL. S-1 is an oral 5-fluorouracil derivative, and phase II trials showed good clinical efficacy and tolerability. We conducted a phase III randomized controlled trial to establish non-inferiority of S-1 in overall survival (OS) and superiority in HRQOL to taxanes, when given as first-line chemotherapy for MBC. Methods: Patients with HER2-negative non-life-threatening MBC, naive to chemotherapy for metastatic disease, were randomly assigned to the taxane or S-1 groups. In the taxane group, patients received docetaxel 60-75mg/m2 q3w, paclitaxel 80-100mg/m2 q1w, or paclitaxel 175 mg/m2 q3w according to institutional policy. In the S-1 group, patients received S-1 40–60 mg twice daily based on body surface area using a 28 days on;14 days off regimen. Treatment was repeated until tumor progression or for at least 6 cycles (taxane) or 4 cycles (S-1). After failure of the first-line protocol therapy, another cytotoxic agent was administered, based on the investigator’s discretion. HRQOL was assessed with the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, the Patient Neurotoxicity Questionnaire (PNQ) and the EQ-5D at baseline and 3, 6, 12 months after the start of the treatment. The primary endpoint was OS. Secondary endpoints were time to treatment failure (TTF), adverse events, and HRQOL. Results: A total of 618 women were enrolled. After a median follow-up of 34.6 months, median OS was 37.2 months in the taxane group (n=309) and 35.0 months in the S-1 group (n=309) (hazard ratio [HR] 1.05, 95% confidence interval [CI] 0.86–1.27, non-inferiority test p=0.015). Median TTF was 8.9 months in the taxane group and 8.0 months in the S-1 group (HR 1.10, 95% CI 0.93–1.30, p=0.022). The incidence of the following grade 3-4 adverse events, allergic reaction, edema and sensory neuropathy, were statistically significantly more frequent in the taxane group (p=0.038, 0.0013 and 0.0077, respectively). Hematologic and non hematologic toxicities except above did not differ significantly between the two groups. The results of the EORTC QLQ-C30 under study treatment indicated that the S-1 was better than the taxanes in global health status/QOL (p=0.044), physical functioning (p=0.002), role functioning (p=0.002), emotional functioning (p=0.004), cognitive functioning (p=0.026), social functioning (p Conclusions: This study clearly demonstrated that S-1 was superior to taxanes in terms of HRQOL and toxicity, without compromising the prolonged OS. S-1 should be considered as a new standard for first-line chemotherapy for MBC. We are conducting another similar trial (UMI05449) that compares first-line anthracycline with S-1 in terms of OS and HRQOL. Citation Format: Takanori Watanabe, Kojiro Shimozuma, Kentaro Imi, Hiroyoshi Doihara, Hiromitsu Akabane, Hiroaki Ueo, Shinji Ohno, Masahiro Kashiwaba, Atsushi Fukuuchi, Kenichi Watanabe, Michiko Tsuneizumi, Hirotsugu Isaka, Yukari Uemura, Yasuo Ohashi, Hirofumi Mukai. Randomized phase III trial of taxanes versus S-1 as first-line chemotherapy for metastatic breast cancer (SELECT BC: CSPOR- MBC01) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-10-01." @default.
• W869271457 created "2016-06-24" @default.
• W869271457 creator A5007957984 @default.
• W869271457 creator A5016758628 @default.
• W869271457 creator A5019325551 @default.
• W869271457 creator A5027687722 @default.
• W869271457 creator A5027854342 @default.
• W869271457 creator A5035092212 @default.
• W869271457 creator A5036816356 @default.
• W869271457 creator A5046753596 @default.
• W869271457 creator A5055351763 @default.
• W869271457 creator A5056628460 @default.
• W869271457 creator A5068445895 @default.
• W869271457 creator A5072654198 @default.
• W869271457 creator A5078339228 @default.
• W869271457 creator A5089829213 @default.
• W869271457 creator A5090955736 @default.
• W869271457 date "2015-04-30" @default.
• W869271457 modified "2023-10-02" @default.
• W869271457 title "Abstract P3-10-01: Randomized phase III trial of taxanes versus S-1 as first-line chemotherapy for metastatic breast cancer (SELECT BC: CSPOR- MBC01)" @default.
• W869271457 doi "https://doi.org/10.1158/1538-7445.sabcs14-p3-10-01" @default.
• W869271457 hasPublicationYear "2015" @default.
• W869271457 type Work @default.
• W869271457 sameAs 869271457 @default.
• W869271457 citedByCount "0" @default.
• W869271457 crossrefType "proceedings-article" @default.
• W869271457 hasAuthorship W869271457A5007957984 @default.
• W869271457 hasAuthorship W869271457A5016758628 @default.
• W869271457 hasAuthorship W869271457A5019325551 @default.
• W869271457 hasAuthorship W869271457A5027687722 @default.
• W869271457 hasAuthorship W869271457A5027854342 @default.
• W869271457 hasAuthorship W869271457A5035092212 @default.
• W869271457 hasAuthorship W869271457A5036816356 @default.
• W869271457 hasAuthorship W869271457A5046753596 @default.
• W869271457 hasAuthorship W869271457A5055351763 @default.
• W869271457 hasAuthorship W869271457A5056628460 @default.
• W869271457 hasAuthorship W869271457A5068445895 @default.
• W869271457 hasAuthorship W869271457A5072654198 @default.
• W869271457 hasAuthorship W869271457A5078339228 @default.
• W869271457 hasAuthorship W869271457A5089829213 @default.
• W869271457 hasAuthorship W869271457A5090955736 @default.
• W869271457 hasConcept C121608353 @default.
• W869271457 hasConcept C126322002 @default.
• W869271457 hasConcept C143998085 @default.
• W869271457 hasConcept C168563851 @default.
• W869271457 hasConcept C197934379 @default.
• W869271457 hasConcept C203092338 @default.
• W869271457 hasConcept C2775930923 @default.
• W869271457 hasConcept C2776694085 @default.
• W869271457 hasConcept C2777292972 @default.
• W869271457 hasConcept C2777511904 @default.
• W869271457 hasConcept C2778336483 @default.
• W869271457 hasConcept C2778375690 @default.
• W869271457 hasConcept C2781190966 @default.
• W869271457 hasConcept C2781413609 @default.
• W869271457 hasConcept C530470458 @default.
• W869271457 hasConcept C71924100 @default.
• W869271457 hasConceptScore W869271457C121608353 @default.
• W869271457 hasConceptScore W869271457C126322002 @default.
• W869271457 hasConceptScore W869271457C143998085 @default.
• W869271457 hasConceptScore W869271457C168563851 @default.
• W869271457 hasConceptScore W869271457C197934379 @default.
• W869271457 hasConceptScore W869271457C203092338 @default.
• W869271457 hasConceptScore W869271457C2775930923 @default.
• W869271457 hasConceptScore W869271457C2776694085 @default.
• W869271457 hasConceptScore W869271457C2777292972 @default.
• W869271457 hasConceptScore W869271457C2777511904 @default.
• W869271457 hasConceptScore W869271457C2778336483 @default.
• W869271457 hasConceptScore W869271457C2778375690 @default.
• W869271457 hasConceptScore W869271457C2781190966 @default.
• W869271457 hasConceptScore W869271457C2781413609 @default.
• W869271457 hasConceptScore W869271457C530470458 @default.
• W869271457 hasConceptScore W869271457C71924100 @default.
• W869271457 hasLocation W8692714571 @default.
• W869271457 hasOpenAccess W869271457 @default.
• W869271457 hasPrimaryLocation W8692714571 @default.
• W869271457 hasRelatedWork W10233532 @default.
• W869271457 hasRelatedWork W11467293 @default.
• W869271457 hasRelatedWork W18425634 @default.
• W869271457 hasRelatedWork W1852032 @default.
• W869271457 hasRelatedWork W2337926 @default.
• W869271457 hasRelatedWork W2976006 @default.
• W869271457 hasRelatedWork W3598312 @default.
• W869271457 hasRelatedWork W5038423 @default.
• W869271457 hasRelatedWork W9309986 @default.
• W869271457 hasRelatedWork W19634549 @default.
• W869271457 isParatext "false" @default.
• W869271457 isRetracted "false" @default.
• W869271457 magId "869271457" @default.
• W869271457 workType "article" @default.